Breast cancer drug IBRANCE® under Real-World watch in korea
NCT ID NCT03445637
First seen Jan 09, 2026
Summary
This completed study looked at how safe and effective the drug IBRANCE® is for women with advanced breast cancer when used in everyday medical practice. Researchers tracked 552 women in Korea for side effects and how well the drug worked. The goal was to gather real-world information to support the drug's approved use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib (IBRANCE®)
What this could lead to
If successful, this study could confirm that IBRANCE® is safe and effective in real-world use for advanced breast cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only included Korean women, so findings may not apply to other groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.